ATE319436T1 - Nanopartikel - Google Patents

Nanopartikel

Info

Publication number
ATE319436T1
ATE319436T1 AT01974554T AT01974554T ATE319436T1 AT E319436 T1 ATE319436 T1 AT E319436T1 AT 01974554 T AT01974554 T AT 01974554T AT 01974554 T AT01974554 T AT 01974554T AT E319436 T1 ATE319436 T1 AT E319436T1
Authority
AT
Austria
Prior art keywords
carbohydrate
nanoparticles
immobilising
therapeutics
studying
Prior art date
Application number
AT01974554T
Other languages
English (en)
Inventor
Soledad Penades
Javier Rojo
Manuel Martin-Lomas
Original Assignee
Consejo Superior Investigacion
Midatech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9901442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE319436(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Consejo Superior Investigacion, Midatech Ltd filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of ATE319436T1 publication Critical patent/ATE319436T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mathematical Physics (AREA)
  • Optics & Photonics (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
AT01974554T 2000-10-16 2001-10-16 Nanopartikel ATE319436T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0025414.4A GB0025414D0 (en) 2000-10-16 2000-10-16 Nanoparticles

Publications (1)

Publication Number Publication Date
ATE319436T1 true ATE319436T1 (de) 2006-03-15

Family

ID=9901442

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01974554T ATE319436T1 (de) 2000-10-16 2001-10-16 Nanopartikel
AT05026069T ATE468112T1 (de) 2000-10-16 2001-10-16 Nanopartikel

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05026069T ATE468112T1 (de) 2000-10-16 2001-10-16 Nanopartikel

Country Status (10)

Country Link
US (3) US7364919B2 (de)
EP (2) EP1326589B1 (de)
JP (2) JP4467882B2 (de)
AT (2) ATE319436T1 (de)
AU (2) AU9406801A (de)
CA (1) CA2424734C (de)
DE (2) DE60142192D1 (de)
ES (2) ES2346319T5 (de)
GB (1) GB0025414D0 (de)
WO (1) WO2002032404A2 (de)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
FI118061B (fi) * 2001-09-24 2007-06-15 Beanor Oy Menetelmä ja bioanturi analyysiä varten
FI115166B (fi) * 2001-12-31 2005-03-15 Biofons Oy Diagnostisia menetelmiä
WO2004038037A2 (en) 2002-09-20 2004-05-06 Intel Corporation Controlled alignment of nano-barcodes encoding specific information for scanning probe microscopy (spm) reading
US7361821B2 (en) * 2002-09-20 2008-04-22 Intel Corporation Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (SPM) reading
US7695738B2 (en) * 2003-02-19 2010-04-13 Academia Sinica Carbohydrate encapsulated nanoparticles
WO2005010481A2 (en) * 2003-06-03 2005-02-03 The Regents Of The University Of California Preparation and use of gold glyconanoparticles
GB0313259D0 (en) * 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
EP1687024B1 (de) * 2003-11-05 2011-10-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Kohlenhydrat-antigen-nanoteilchen-konjugate und ihre verwendungen als antimetastatische mittel bei der behandlung von krebs
ES2242528B1 (es) * 2004-03-25 2006-12-01 Consejo Sup. Investig. Cientificas Nanoparticulas magneticas de metales nobles.
EP1756289B1 (de) * 2004-05-24 2015-01-14 Midatech Ltd. Rna-liganden umfassende nanopartikel
GB0411537D0 (en) * 2004-05-24 2004-06-23 Midatech Ltd Nanoparticles comprising rna ligands
US20070249063A1 (en) * 2004-08-30 2007-10-25 Deshong Philip R Biosensors
WO2006037979A2 (en) * 2004-10-01 2006-04-13 Midatech Limited Nanoparticles comprising antigens and adjuvants and immunogenic structure
JP4550555B2 (ja) * 2004-11-17 2010-09-22 国立大学法人 東京医科歯科大学 量子ドット（Ｑｄｏｔ）−ナノゲル複合体の調製
JP2006182673A (ja) * 2004-12-27 2006-07-13 Kenji Yamamoto マーカー付き医薬
JP4484151B2 (ja) * 2005-03-28 2010-06-16 国立大学法人滋賀大学 ヒト血液型試薬
US9297092B2 (en) 2005-06-05 2016-03-29 Qd Vision, Inc. Compositions, optical component, system including an optical component, devices, and other products
US8845927B2 (en) * 2006-06-02 2014-09-30 Qd Vision, Inc. Functionalized nanoparticles and method
EP1922419A4 (de) * 2005-06-10 2010-11-17 Life Technologies Corp Verfahren und system zur genetischen multiplex-analyse
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP1919507A2 (de) * 2005-08-04 2008-05-14 Thomas William Rademacher Nanoteilchen mit antibakteriellen liganden
GB0517077D0 (en) * 2005-08-19 2005-09-28 Isis Innovation Imaging agent
JP4670659B2 (ja) * 2006-01-25 2011-04-13 住友電気工業株式会社 蛍光標識金属粉末、ならびに該蛍光標識金属粉末を含有する異方導電膜、実装品
US8143072B2 (en) * 2006-02-08 2012-03-27 The University Of Toledo System for detecting nanoparticles using modulated surface plasmon resonance
US8849087B2 (en) * 2006-03-07 2014-09-30 Qd Vision, Inc. Compositions, optical component, system including an optical component, devices, and other products
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US9212056B2 (en) 2006-06-02 2015-12-15 Qd Vision, Inc. Nanoparticle including multi-functional ligand and method
US8329635B2 (en) * 2006-06-20 2012-12-11 Bracco Imaging S.P.A. Method for the preparation of specific antibodies against saccharidic antigens
WO2008063662A2 (en) * 2006-11-21 2008-05-29 Black Lion Pharmaceuticals Gold (iii) chloride compositions for cancer
US9239329B2 (en) 2006-12-18 2016-01-19 Japan Science And Technology Agency Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods
US20080317768A1 (en) 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
ES2320837B1 (es) 2007-07-26 2010-03-04 Consejo Superior De Investigaciones Cientificas Dispositivo de hipertermia y su utilizacion con nanoparticulas.
US9175015B2 (en) 2007-08-22 2015-11-03 Colorado School Of Mines Gold nanoparticle conjugates and uses thereof
EP2033660A1 (de) * 2007-09-05 2009-03-11 Freie Universität Berlin Funktionalisierte Nanopartikel zur Hemmung Selectin-vermittelter Zelladhäsion
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
DE102007055386B4 (de) * 2007-11-20 2015-07-16 Boehringer Ingelheim Vetmedica Gmbh Verfahren zur Kalibrierung eines Sensorelements
US20100285994A1 (en) * 2007-12-28 2010-11-11 Shiga University Of Medical Science Gold nanoparticle composition, dna chip, near infrared absorbent, drug carrier for drug delivery system (dds), coloring agent, biosensor, cosmetic, composition for in vivo diagnosis and composition for therapeutic use
RU2395268C2 (ru) * 2008-01-15 2010-07-27 Евгений Петрович Гребенников Способ получения лекарственного средства
EP2123269A1 (de) * 2008-05-21 2009-11-25 Freie Universität Berlin Mit sulfatierten Aminalkoholen funktionalisierte Nanopartikel zur Hemmung selectinvermittelter Zelladhäsion
WO2010096464A1 (en) * 2009-02-18 2010-08-26 Boyes Stephen G Gold/lanthanide nanoparticle conjugates and uses thereof
WO2010087912A1 (en) * 2009-01-30 2010-08-05 University Of Utah Research Foundation Hydrogels crosslinked with gold nanoparticles and methods of making and using thereof
WO2010138192A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
EA023897B1 (ru) 2009-08-26 2016-07-29 Селекта Байосайенсиз, Инк. Композиции, которые индуцируют хелперное действие т-клеток
EP2561072A4 (de) 2010-04-20 2016-04-06 Univ Florida Nanozyme, verfahren zur herstellung von nanozymen und verfahren zur verwendung von nanozymen
US8962345B2 (en) * 2010-05-21 2015-02-24 The United States Of America As Represented By The Secretary Of Commerce Method of characterizing glycans attached to glycoproteins
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
CA2807271C (en) 2010-06-10 2018-07-31 Midatech Limited Nanoparticle film delivery systems
AU2011263546B2 (en) 2010-06-10 2015-01-22 Midatech Limited Peptide-carrying nanoparticles
EP2640190A4 (de) 2010-11-05 2016-05-11 Selecta Biosciences Inc Modifizierte nikotinische verbindungen und zugehörige verfahren
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
JP5754309B2 (ja) * 2011-09-02 2015-07-29 コニカミノルタ株式会社 表面プラズモン励起増強蛍光分光法を利用して蛍光量を測定する定量分析方法ならびにそれに用いられる定量分析用キットおよびアナライト解離抑制剤
AU2012306243B2 (en) 2011-09-07 2016-10-20 Midatech Limited Nanoparticle-peptide compositions
MX2014002764A (es) 2011-09-07 2014-12-04 Midatech Ltd Vacunas en nanoparticulas para tumor.
US9772305B2 (en) 2011-09-15 2017-09-26 Arizona Board Of Regents On Behalf Of Arizona State University System and method for small molecule detection
GB201301991D0 (en) 2013-02-05 2013-03-20 Midatech Ltd Permeation enhanced active-carrying nanoparticles
GB201302427D0 (en) 2013-02-12 2013-03-27 Midatech Ltd Nanoparticle delivery compositions
GB201303787D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticle peptide compositions
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
KR101329646B1 (ko) 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
BR112015027291A8 (pt) * 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
IL295392A (en) 2013-06-04 2022-10-01 Selecta Biosciences Inc Repeated administration of non-immunosupressive antigen specific immunotherapeutics
TW201521762A (zh) 2013-08-14 2015-06-16 Univ Florida 奈米酶、製備奈米酶的方法、以及使用奈米酶的方法
US10266544B2 (en) 2013-09-29 2019-04-23 St. Jude Children's Research Hospital, Inc. Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents
GB201401706D0 (en) 2014-01-31 2014-03-19 Midatech Ltd Nanoparticle-insulin and insulin analogue compositions
EP3131566B1 (de) 2014-04-15 2022-10-05 The Regents of the University of California Bi-terminale pegylierte integrinbindende peptide und verfahren zur verwendung davon
US20150374815A1 (en) 2014-06-25 2015-12-31 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
US9910035B1 (en) 2014-07-16 2018-03-06 Verily Life Sciences Llc Polyvalent functionalized nanoparticle-based in vivo diagnostic system
WO2016037164A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
EP3237016A1 (de) 2014-12-23 2017-11-01 Midatech Ltd Nanopartikel und deren verwendung in der krebstherapie
KR102588589B1 (ko) * 2015-05-18 2023-10-16 히데미 카키하라 항균 물질 및 액상 항균제 및 액상 항균제의 제조 방법
CN112933094B (zh) 2015-06-18 2024-07-26 听治疗有限责任公司 预防和治疗听力损失的方法和组合物
GB2541166A (en) 2015-07-24 2017-02-15 Midatech Ltd Nanoparticle-based liver-targeting therapy and imaging
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
IL318183A (en) 2016-03-11 2025-03-01 Selecta Biosciences Inc Formulations and doses of pegylated uricase
CA3021645A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
EP3518956A1 (de) 2016-09-27 2019-08-07 Selecta Biosciences, Inc. Rekombinante immunotoxine zur verwendung bei der behandlung von krebs
AU2018206291A1 (en) 2017-01-03 2019-07-25 Emergex Vaccines Holding Limited Universal influenza vaccine compositions
WO2018129268A1 (en) 2017-01-07 2018-07-12 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
GB201701745D0 (en) 2017-02-02 2017-03-22 Midatech Ltd Nanoparticle-based liver-targeting therapy and imaging
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
US10543231B2 (en) 2017-05-19 2020-01-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
GB2563602B (en) 2017-06-19 2022-06-08 Middlesex Univ Higher Education Corporation Method and apparatus for imaging
WO2019058133A2 (en) 2017-09-21 2019-03-28 Emergex Vaccines Holding Limited MHC CLASS I ASSOCIATED PEPTIDES FOR THE PREVENTION AND TREATMENT OF ZIKA VIRUS
MX2020003838A (es) 2017-10-13 2020-08-06 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral.
US11690904B2 (en) 2018-01-06 2023-07-04 Emergex Vaccines Holding Limited MHC class I associated peptides for prevention and treatment of multiple flavi virus
EP3773706A1 (de) 2018-03-29 2021-02-17 Emergex Vaccines Holdings Limited Impfstoffzusammensetzungen
JP2021519762A (ja) 2018-03-29 2021-08-12 イマージェクス ヴァクシンズ ホールディング リミテッドＥｍｅｒｇｅｘ Ｖａｃｃｉｎｅｓ Ｈｏｌｄｉｎｇ Ｌｉｍｉｔｅｄ ワクチン組成物
MX2020012373A (es) 2018-05-18 2021-02-09 Emergex Vaccines Holding Ltd Vacuna de peptido inverso.
JP2021531282A (ja) 2018-07-16 2021-11-18 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences, Inc. Ｏｔｃコンストラクトおよびベクターの方法および組成物
EP3823676A1 (de) 2018-07-16 2021-05-26 Selecta Biosciences, Inc. Verfahren und zusammensetzungen von mma-konstrukten und vektoren
GB201819430D0 (en) 2018-11-29 2019-01-16 Midatech Ltd Therapeutic compounds, nanoparticles and uses thereof
GB201820471D0 (en) 2018-12-14 2019-01-30 Midatech Ltd Nanoparticle-based therapy of inflammatory disorders
GB201820470D0 (en) 2018-12-14 2019-01-30 Midatech Ltd Antifolate-carrying nanoparticles and their use in medicine
BR112021021566A2 (pt) 2019-04-28 2022-04-19 Selecta Biosciences Inc Métodos para tratamento de indivíduos com imunidade preexistente a vetores de transferência viral
BR112021023594A2 (pt) 2019-05-28 2022-02-08 Selecta Biosciences Inc Métodos e composições para resposta imune de vetor de transferência antiviral atenuada
EP3980784A1 (de) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulierungen und dosen von pegylierter uricase
US11890299B2 (en) 2019-06-27 2024-02-06 Hologic, Inc. Ablation agent and methods of use
EP4048269A1 (de) 2019-10-21 2022-08-31 Selecta Biosciences, Inc. Verfahren und zusammensetzungen zum behandeln von lebererkrankungen und -störungen
CN110755640B (zh) * 2019-10-21 2022-06-10 浙江师范大学 一种金铂复合纳米诊疗剂的制备方法及应用
CN118384281A (zh) 2019-11-08 2024-07-26 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
CA3164781A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Methods of sequencing by synthesis using a consecutive labeling scheme
EP4110334A1 (de) 2020-02-26 2023-01-04 Selecta Biosciences, Inc. Verfahren und zusammensetzungen mit synthetischen nanoträgern mit immunsuppressivum
US20230147052A1 (en) 2020-04-14 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for inducing autophagy
GB202008250D0 (en) 2020-06-02 2020-07-15 Emergex Vaccines Holding Ltd Diagnosis, prevention and treatment of coronavirus infection
CN111590087B (zh) * 2020-06-04 2023-04-18 安徽医科大学 荧光金纳米簇的制备方法、制得的荧光金纳米簇及其应用
US20220133864A1 (en) 2020-11-04 2022-05-05 Selecta Biosciences, Inc. Methods and compositions for reducing immune responses against immunoglobulin proteases
AU2022206197A1 (en) 2021-01-05 2023-07-13 Selecta Biosciences, Inc. Viral vector dosing protocols
EP4294435A1 (de) 2021-02-16 2023-12-27 Emergex Vaccines Holding Limited Reverse peptide aus coronavirus für immunogene zwecke
CN113059177A (zh) * 2021-03-05 2021-07-02 江苏师范大学 一种金/银/金核壳结构的纳米粒子及其合成方法
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
AU2022253064A1 (en) 2021-04-09 2023-10-19 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2022253917A1 (en) 2021-06-02 2022-12-08 Emergex Vaccines Holding Limited Human coronavirus 229e derived peptides
CN113500199B (zh) * 2021-06-10 2022-11-08 浙江大学 一种基于金铂双金属活性氧自生成纳米材料的制备方法及其产品和应用
JP2024539646A (ja) 2021-10-12 2024-10-29 カーティザン セラピューティクス，インコーポレーテッド ウイルスベクター投薬プロトコル
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023064887A1 (en) 2021-10-15 2023-04-20 The Board Of Trustees Of The University Of Illinois Mechanochemical dynamic therapy for focal cancer treatment
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
CA3264659A1 (en) 2022-08-11 2024-02-15 Cartesian Therapeutics, Inc. COMPOSITIONS AND PROCESSES ASSOCIATED WITH IMMUNOGLOBULIN PROTEASES AND FUSION THEREOF
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7807532A (nl) * 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
WO1983000173A1 (en) 1981-07-02 1983-01-20 Eynon, David, Leslie Flow box
WO1983001738A1 (en) * 1981-11-12 1983-05-26 SCHRÖDER, Ulf Intravascularly administrable, magnetically responsive nanosphere or manoparticle, a process for the production thereof, and the use thereof
SE8704157L (sv) 1987-10-26 1989-04-27 Carbomatrix Ab C O Ulf Schroed Superparamagnetiska partiklar och foerfarande foer framstaellning daerav samt anvaendning
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5248772A (en) * 1992-01-29 1993-09-28 Coulter Corporation Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents
US5766572A (en) * 1992-08-05 1998-06-16 Meito Sangyo Kabushiki Kaisha Water-soluble carboxypolysaccharide-magnetic iron oxide complex having a small particle diameter
WO1995031220A1 (en) 1994-05-12 1995-11-23 Otsuka Pharmaceutical Co., Ltd. Contrast medium for magnetic resonance imaging
FR2777193B1 (fr) 1998-04-14 2001-06-08 Coletica Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie
EP1073902A2 (de) * 1998-04-20 2001-02-07 University Of North Carolina At Chapel Hill Naonometerpartikel mit reaktiver schicht
CA2402955C (en) 2000-03-28 2010-03-09 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles

Also Published As

Publication number Publication date
US20120071443A1 (en) 2012-03-22
US20080145441A1 (en) 2008-06-19
ES2346319T5 (es) 2014-03-18
EP1671625A1 (de) 2006-06-21
DE60117828T2 (de) 2006-11-16
EP1671625B2 (de) 2013-12-25
AU9406801A (en) 2002-04-29
ES2262684T3 (es) 2006-12-01
US20040052729A1 (en) 2004-03-18
JP2009242418A (ja) 2009-10-22
JP2004511511A (ja) 2004-04-15
ATE468112T1 (de) 2010-06-15
CA2424734C (en) 2011-10-11
CA2424734A1 (en) 2002-04-25
US8080431B2 (en) 2011-12-20
DE60142192D1 (de) 2010-07-01
EP1326589A2 (de) 2003-07-16
JP4467882B2 (ja) 2010-05-26
US8790934B2 (en) 2014-07-29
DE60117828D1 (de) 2006-05-04
AU2001294068B2 (en) 2005-12-22
GB0025414D0 (en) 2000-11-29
EP1671625B1 (de) 2010-05-19
WO2002032404A3 (en) 2002-08-22
WO2002032404A2 (en) 2002-04-25
EP1326589B1 (de) 2006-03-08
US7364919B2 (en) 2008-04-29
ES2346319T3 (es) 2010-10-14

Similar Documents

Publication Publication Date Title
ATE468112T1 (de) Nanopartikel
ATE487496T1 (de) Mit einem liganden verknüpfte magnetische nanoteilchen
ATE236656T1 (de) Eingeschränktes multifunktionelles reagens zur oberflächenmodifikation
CY1109554T1 (el) Μεθοδοι και αντιδραστηρια για την ανιχνευση ενδοτοξινης
DE69434871D1 (de) Erhöhung von Chemilumineszenz in Assays
ATE412774T1 (de) Parallele genotypisierung mehrerer patientenproben
ATE354607T1 (de) Opake folie aus polymilchsäuren
WO2008028160A3 (en) Substrates, systems and methods for analyzing materials
ATE378399T1 (de) Magnetische manipulation von biologischen proben
ES2095331T3 (es) Tecnica de ensayo.
ATE430712T1 (de) Analyse von molekülen durch translokation durch eine beschichtete öffnung
ATE442227T1 (de) Magnetische mehrzweck-halbklemme
DE50300739D1 (de) Vorrichtung zur aufnahme von substraten
WO2004090506A3 (en) Surfaces that selectively bind to moieties
ATE70916T1 (de) Mit ueberzuegen versehene formkoerper zur bindung von bioaffinen substanzen.
DE60017017D1 (de) Immuntest unter verwendung von partikeln mit kaseinumhüllungen
SE0001660D0 (sv) Separation of glyco-containing entities
DE60133937D1 (de) Vorrichtung zur Herstellung von Mikromatrizen wobei die Vorrichtung in inkrementellen Etappen mechanisch eingestellt wird
EP0441470A3 (en) Process for separating and measuring trace components
Kiss et al. A coagulation factor becomes useful in the study of acute leukemias: studies with blood coagulation factor XIII
DE50108241D1 (de) Verfahren zur herstellung von biopolymer-feldern mit echtzeitkontrolle
Bronstein et al. Enhancement of chemiluminescent assays
ATE128236T1 (de) Verwendung von atelokollagen als festträger für die fixierung eines spezifischen fängers.
BUCUREASA et al. COMPARATIVE DETERMINATION OF ZINC FROM WALNUT LEAVES AND KERNEL
CALL Fourth Eurographics Workshop on Graphics Hardware

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326589

Country of ref document: EP